Clinical trial · no report yet · Phase 1/Phase 2
NCT04849910
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS
- NCT04849910 ↗
- Terminated
- Vor Biopharma
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Bluesky threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients With Acute Myeloid Leukemia Who Are at High-Risk for Leukemia Relapse Following Hematopoietic Cell Transplantation
- Phase
- Phase 1/Phase 2
- Status
- Terminated
- Conditions
- Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
- Interventions
- VOR33; Mylotarg
- Arms
- Cohort 1 · Experimental
- Cohort 2 · Experimental
- Cohort 3 · Experimental
- Enrollment
- 67
- Primary outcomes
- Incidence of neutrophil engraftment
- Sponsor
- Vor Biopharma
- Start
- Dec 16, 2021
- Primary completion
- May 28, 2025
- Results posted
- No
- Registry record
- NCT04849910 · updated Jul 29, 2025
Publications
linked from the registry- DiPersio JF, Koehne G, Shah NN, Bernard L, Suh HC, Koura D, Tamari R, Mushtaq MU, Maakaron J, Rimando J, Kennedy VE, Patel SS, Hudson C, Loken MR, Slapak CA, Lloyd DM, Stanizzi DA, Lee-Sundlov MM, Thosar S, Mundelboim G, Guo G, Ge HG, Li BE, Xavier-Ferrucio J, Hyzy SL, Lin MI, Raffel GD, Cooper BW. CRISPR-Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial. Nat Med. 2026 May;32(5):1763-1772. doi: 10.1038/s41591-026-04362-1. Epub 2026 May 12. PubMed 42120728
- Lydeard JR, Lin MI, Ge HG, Halfond A, Wang S, Jones MB, Etchin J, Angelini G, Xavier-Ferrucio J, Lisle J, Salvadore K, Keschner Y, Mager H, Scherer J, Hu J, Mukherjee S, Chakraborty T. Development of a gene edited next-generation hematopoietic cell transplant to enable acute myeloid leukemia treatment by solving off-tumor toxicity. Mol Ther Methods Clin Dev. 2023 Oct 13;31:101135. doi: 10.1016/j.omtm.2023.101135. eCollection 2023 Dec 14. PubMed 38027064